Table 4 Performance of the GB kit in the presence of interfering compounds
From: Performance of commercially available anti-HDV enzyme-linked immunosorbent assays in Taiwan
Specimen | Interfering compound | mean COI | ± | std. Dev. | p-value |
|---|---|---|---|---|---|
Serum | TG (−) | 3.65 | ± | 0.60 | 0.87 |
TG (+) | 3.59 | ± | 0.09 | ||
BL (−) | 2.95 | ± | 0.83 | 0.77 | |
BL (+) | 2.75 | ± | 0.67 | ||
HB (−) | 3.85 | ± | 0.38 | 0.62 | |
HB (+) | 3.68 | ± | 0.40 | ||
HAMA (−) | 3.60 | ± | 0.16 | 0.43 | |
HAMA (+) | 3.80 | ± | 0.35 | ||
MAPC (−) | 3.26 | ± | 0.49 | 0.20 | |
MAPC (+) | 3.89 | ± | 0.52 | ||
EDTA-treated plasma | TG (−) | 4.09 | ± | 0.60 | 0.24 |
TG (+) | 3.57 | ± | 0.23 | ||
BL (−) | 3.65 | ± | 0.84 | 0.48 | |
BL (+) | 3.24 | ± | 0.39 | ||
HB (−) | 4.59 | ± | 0.26 | 0.03 | |
HB (+) | 3.90 | ± | 0.26 | ||
HAMA (−) | 4.67 | ± | 0.27 | 0.23 | |
HAMA (+) | 4.43 | ± | 0.11 | ||
MAPC (−) | 4.09 | ± | 0.09 | 0.01 | |
MAPC (+) | 5.02 | ± | 0.30 |